APA (7th ed.) Citation

Fischer, T., Reifenrath, C., Hess, G. R., Corsetti, M. T., Kreil, S., Beck, J., . . . Huber, C. (2002). Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia, 16(7), . https://doi.org/10.1038/sj.leu.2402565

Chicago Style (17th ed.) Citation

Fischer, Thomas, et al. "Safety and Efficacy of STI-571 (imatinib Mesylate) in Patients with Bcr/abl-positive Chronic Myelogenous Leukemia (CML) After Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)." Leukemia 16, no. 7 (2002). https://doi.org/10.1038/sj.leu.2402565.

MLA (9th ed.) Citation

Fischer, Thomas, et al. "Safety and Efficacy of STI-571 (imatinib Mesylate) in Patients with Bcr/abl-positive Chronic Myelogenous Leukemia (CML) After Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)." Leukemia, vol. 16, no. 7, 2002, https://doi.org/10.1038/sj.leu.2402565.